Introduction
Asthma is a chronic inflammatory airway disease characterized by episodes of reversible airway obstruction, bronchial hyperresponsiveness and chronic pulmonary inflammation [1] . In the last 3 decades, the prevalence of asthma has been increasing, particularly in children. The last estimate of asthma prevalence was 300 million worldwide [1] .
The imbalance in immune responses tending towards type 2 and inflammatory responses has been described to be of importance in the immunopathogenesis of asthma in children [1, 2] . IL-33 is a relatively new member of the IL-1 family of cytokines that mediates both inflammatory and type 2 preallergenic responses. IL-33 secreted by epithelial cells, by binding to its own receptor, ST2, activates the immune system [3] . In mouse models, IL-33 has been found to amplify IgE synthesis, tryptase activity, eotaxin production, histamine release, mast cell degranulation and airway smooth-muscle contractility [4] [5] [6] .
immune responses but does not affect IL-33 expression in fibroblasts and airway smooth-muscle cells taken from airway biopsies of children with severe steroid-resistant asthma [5, 7, 8] . In mouse models of allergic airway disease, the IL-33/ST2 axis induced airway remodeling independent of IL-13 [8] . However, the association of serum IL-33 with asthma severity has still to be studied. We aimed to investigate the serum IL-33 in patients with asthma compared to controls and the association of serum IL-33 with asthma severity.
Materials and Methods
This age-and sex-matched case-control study was conducted on 124 children under the age of 18 years. The case group comprised 61 children with asthma; 63 healthy children free of any allergic or other chronic diseases were included as controls. Controls were recruited via announcements at schools and in newspapers, while cases with asthma were recruited from the outpatient clinic for asthma and allergy of the Children's Medical Center Hospital. A thorough history was taken and medical records were reviewed for recurrent wheezing, food allergy and atopic dermatitis. Forced expiratory volume in 1 s (FEV 1 ) was measured for all participants. Asthma was diagnosed and classified according to published guidelines [9] . Following diagnosis, asthma severity was categorized into mild (intermittent), moderate and severe. Patients with mild asthma were those with daytime symptoms on <2 days and night waking 3-4 times per week, an FEV 1 >80% of predicted as well as those experiencing minor limitations in their daily activities. Children with severe asthma had frequent daytime symptoms and night waking maybe every night, an FEV 1 <60% of predicted and experienced major limitations in their daily activities. Patients with moderate asthma had features between these two extremes.
We also categorized the children as having controlled and uncontrolled asthma with respect to their medication needs for control of the disease. Children with controlled asthma had ≤ 2 daily symptoms or reliever requirements per week and had had no night waking or activity limitation due to asthma during the last month while on adequate treatment. However, uncontrolled asthmatics had frequent daily symptoms and reliever requirements as well as night waking and activity limitations due to their asthma. The participants and their parents received detailed information regarding the study protocol. Informed consent was obtained from the parents of all participants. The institutional review board approved the study and the study protocol was in accordance with the guidelines laid down by the latest version of the Helsinki Declaration (2008).
For the case group, the measurement of serum eosinophil count and IL-33 was done at times other than when the children were admitted for asthma attacks. The controls were free of any acute infectious disease at the time of sample collection. Five milliliters of peripheral blood were collected from both patients and controls and were stored at -20 ° C for the measurement of IL-33. Serum IL-33 was measured using sandwich enzyme-linked immunosorbent assay (ELISA, eBiosience cat. No. BMS2048). The sensitivity of this ELISA kit was 0.2 pg/ml. The analysis was done according to the manufacturer's guideline.
Statistical analyses were done using SPPS statistical software v18 (SPSS Inc., Chicago, Ill., USA). The Student t test was used to compare continuous variables and the Fisher exact test for categorical variables between patients with asthma and controls. The Kruskal-Wallis test was used to test associations between IL-33 serum levels and disease severity. p < 0.05 was considered statistically significant.
Results
This case-control study comprised 124 children with a mean age of 9.21 years (range: 6-14 years). Male-to-female ratio was approximately 1: 1 with a total of 68 boys and 56 girls. The case and control groups were matched with respect to age and sex. Table 1 shows the demographics of participants in the case and control groups. Children with asthma had significantly lower FEV 1 than their healthy peers (78.2 ± 8.15 vs. 91.1 ± 8.25%; p <0.001), while serum eosinophil count was higher in children with asthma (5.05 ± 3.01 vs. 2.14 ± 1.58%; p < 0.001). Asthma was mild in 29, moderate in 24 and severe in 8 children. Serum IL-33 was detectable in 45 children with asthma and in 45 in the control group. We were not able to detect serum IL-33 in 34 of the participants. Children with asthma had a significantly higher level of serum IL-33 than the healthy children (15.17 ± 32.3 vs. 0.61 ± 2.16 pg/ml; p = 0.028). More severity of asthma and more serum IL-33 were observed in children with asthma ( fig. 1 , 2 ).
Discussion
We found that children with asthma have higher serum IL-33 levels compared to their healthy peers. The more severe the disease, the more serum IL-33 was detected in blood samples taken from the children with asthma. These findings are in line with the results of pre- Similarly, Raeiszadeh Jahromi et al. [11] demonstrated that serum IL-33 was higher in patients with asthma than in controls and that it had a negative correlation with FEV 1 and forced vital capacity. Interestingly, they showed that serum IL-33 is positively associated with the number of aeroallergen sensitizations. There exists a strong positive correlation between serum IL-33 and induced-sputum IL-33 [12] . The level of IL-33 in sputum is also higher in patients with asthma than in healthy individuals [12] . Serum IL-33 has been shown to be increased in allergic rhinitis more than in allergic asthma [13, 14] . However, Asaka et al. [14] could not detect IL-33 in sera samples taken from patients with allergic rhinitis. They measured IL-33 in the nasal secretions of study participants instead, and found that IL-33 in the nasal secretions of allergic rhinitis patients was significantly higher than in controls and was also associated with total nasal symptom scores. Similarly, we were not able to detect serum IL-33 in 34 of our 124 participants. Of the children with asthma, serum IL-33 was not detectable in 16 patients with mild disease. However, we found that even children with mild asthma had significantly higher serum IL-33 compared to healthy controls.
The important role of IL-33 in initiating airway hyperresponsiveness and inducing airway remodeling has been shown mainly in studies on animal models. Airway smooth-muscle cells as well as innate type 2 lymphocyte cells and Th2 cells produce IL-33 in response to proinflammatory cytokines and aeroallergen exposure [15] . In addition, type 2 cytokines are released from human T cells and innate lymphocyte cells cocultured with rhinovirus entirely dependent on IL-33. This finding emphasizes the role of IL-33 in rhinovirus-induced asthma exacerbation [16] .
IL-33 also acts as a chemoattractant for Th2 cells, leading to their accumulation in lung tissue and creating a vicious cycle of allergic and inflammatory responses in the airways [17] . Activation of the IL-33/ST2 axis leads to the activation of eosinophils, basophils and mast cells, induces histamine and eotaxin release and increases tryptase activity in the airways and lung parenchyma [5, 18] . IL-33 has also been found to increased IgE production via IL-4, in a mouse model [4] , and to enhance airway smoothmuscle cell contractility [5] . Altogether, IL-33 seems to be a potent inducer of inflammatory and allergic responses leading to airway hyperresponsiveness and asthma.
Increased expression of IL-33 has also been linked to poor control of asthma and the steroid-resistant asthma phenotype [7] . In patients with steroid-resistant asthma, 196 steroid treatment may reduce the production of proinflammatory and type 2 cytokines by airway fibroblasts but it does not affect IL-33 expression significantly [8] . IL-33 itself induces the production of collagen and fibronectin by fibroblasts and promotes airway remodeling [8] . These in vitro findings are in line with the results of human studies in which serum IL-33 has been positively correlated with basement membrane thickness on airway biopsies [10] . Given the results of our study and the important role of IL-33 in steroid-resistant asthma, IL-33 can be considered as a marker of asthma severity. However, due to the design of our study, we are unable to draw a causal relationship between increased serum IL-33 and the severity of asthma. Increased IL-33 can still be considered as a consequence of asthma severity, bronchial damage and chronic airway inflammation. In this study, inhaled corticosteroids were the mainstay of therapy, but with an increase in asthma severity, a combination of long-acting β 2 agonists and leukotriene receptor antagonists was used. Unfortunately, we did not record the exact medications used and their dosage. Hence, another limitation of this study is the absence of investigation of the possible effect of each medication on serum IL-33. The strengths of the study are its concise design and the matching of cases and controls. However, several limitations should be acknowledged. As stated, no causality link can be drawn between the increased expression of IL-33 and asthma severity. Moreover, serum IL-33 was undetectable in a considerable number of participants; this lowers the power of the study. Further studies are needed to shed light on the exact role of IL-33 in severe asthma and to pave the way for more efficacious therapies.
